A detailed history of D. E. Shaw & Co., Inc. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 30,765 shares of RCUS stock, worth $512,544. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,765
Previous 67,542 54.45%
Holding current value
$512,544
Previous $1.28 Million 63.29%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$14.59 - $18.48 $536,576 - $679,638
-36,777 Reduced 54.45%
30,765 $468,000
Q1 2024

May 15, 2024

BUY
$14.83 - $20.18 $1 Million - $1.36 Million
67,542 New
67,542 $1.28 Million
Q2 2023

Aug 14, 2023

BUY
$16.97 - $22.03 $169,615 - $220,189
9,995 New
9,995 $202,000
Q4 2022

Feb 14, 2023

BUY
$19.7 - $35.71 $528,038 - $957,170
26,804 New
26,804 $554,000
Q2 2022

Aug 15, 2022

SELL
$17.23 - $37.73 $759,619 - $1.66 Million
-44,087 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$28.92 - $41.83 $8.36 Million - $12.1 Million
-288,907 Reduced 86.76%
44,087 $1.39 Million
Q4 2021

Feb 14, 2022

BUY
$31.38 - $48.47 $4.39 Million - $6.79 Million
140,031 Added 72.57%
332,994 $13.5 Million
Q3 2021

Nov 15, 2021

SELL
$26.93 - $37.68 $4.36 Million - $6.1 Million
-161,983 Reduced 45.64%
192,963 $6.73 Million
Q2 2021

Aug 16, 2021

SELL
$22.75 - $35.77 $4.65 Million - $7.31 Million
-204,363 Reduced 36.54%
354,946 $9.75 Million
Q1 2021

May 17, 2021

SELL
$26.16 - $41.39 $262,227 - $414,893
-10,024 Reduced 1.76%
559,309 $15.7 Million
Q4 2020

Feb 16, 2021

SELL
$17.0 - $32.36 $759,968 - $1.45 Million
-44,704 Reduced 7.28%
569,333 $14.8 Million
Q3 2020

Nov 16, 2020

BUY
$17.14 - $25.47 $2.89 Million - $4.3 Million
168,755 Added 37.9%
614,037 $10.5 Million
Q2 2020

Aug 14, 2020

BUY
$13.97 - $36.56 $6.22 Million - $16.3 Million
445,282 New
445,282 $11 Million
Q1 2020

May 15, 2020

SELL
$8.78 - $19.28 $290,618 - $638,168
-33,100 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$7.33 - $10.79 $242,623 - $357,149
33,100 New
33,100 $334,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.2B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.